Europe Archives - Page 43 of 93 - Journal for Clinical Studies

Current Edition

Europe

With positive phase 3, Intercept to file NASH drug for approval while Inventiva faces a setback

In a crowded field of nonalcoholic steatohepatitis (NASH) hopefuls, Intercept Pharmaceuticals looks to be pulling ahead. In a pivotal phase 3 study, the biotech’s ob...

20 February 2019 Europe | news | Regional News

Continue Reading →

Europe

Orion’s and Bayer’s darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial

American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019: Orion's and Bayer's darolutamide plus androgen deprivation therapy (A...

20 February 2019 Europe | news | North America | Regional News

Continue Reading →

Europe

New Clinerion And Citeline Partnership Simplifies and Strengthens Matchmaking Between Clinical Researchers and Qualified Patients

Collaboration between two companies leads to more informed decisions for clinical researchers, grounded in real-world evidence. Citeline, part of the Informa Pharm...

20 February 2019 Europe | news | North America | Regional News

Continue Reading →

Europe

Our brains indicate how well depression will respond to treatment

(Vienna, 19 February 2019) Working with international partners, a MedUni Vienna research group has shown that imaging techniques carried out prior to treatment indic...

20 February 2019 Europe | news | Regional News

Continue Reading →

Europe

AlzProtect, on Track for a Phase 2 Entry in 2019, for its Drug Candidate AZP2006

LILLE, France, February 20, 2019 --AlzProtect, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease and Progressi...

20 February 2019 Europe | news | Regional News

Continue Reading →

Europe

Merck plans trio of Phase 3 Keytruda studies in prostate cancer

Merck & Co. said Thursday it plans to launch three pivotal Phase 3 studies testing different combination therapies involving its blockbuster immunotherapy Keytru...

20 February 2019 Europe | news | North America | Regional News

Continue Reading →

Europe

Merck’s Keytruda set to become new standard of care for renal cancer patient population after gaining edge over competitors, says GlobalData

Merck & Co Inc’s abstract presentation regarding KEYNOTE-426 trial at ASCO GU 2019 (16 February 2019) has confirmed that Keytruda, an anti-PD-1 therapy, in combi...

20 February 2019 Europe | news | North America | Regional News

Continue Reading →

Europe

New drug shows promise against several aggressive cancers

A new phase I/II open-label, dose-escalation trial has recently tested the effectiveness of a "Trojan horse" drug in treating multiple types of otherwise treatment-r...

14 February 2019 Europe | news | Regional News

Continue Reading →

Europe

Audion Therapeutics and REGAIN Consortium Announce Positive Phase I Results in Patients with Sensorineural Hearing Loss

AMSTERDAM, The Netherlands, February 05, 2019 / -- The REGAIN consortium, led by Audion Therapeutics BV, a company dedicated to the development of the...

14 February 2019 Europe | news | Regional News

Continue Reading →

Europe

Sharp enhances IRT solution with latest investment

Sharp - part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has announced a $650,000 investment into enhancing its Intera...

14 February 2019 Europe | news | North America | Regional News

Continue Reading →